Janssen Reports Submission of Ponesimod’s MAA to EMA for the Treatment of Relapsing Multiple Sclerosis

Janssen Reports Submission of Ponesimod’s MAA to EMA for the Treatment of Relapsing Multiple Sclerosis

Shots:

  • The MAA is based on P-III OPTIMUM study assessing Ponesimod (20mg) vs Teriflunomide (14 mg) in patients with RMS
  • The P-III OPTIMUM study results: @108wks. 30.5% reduction in ARR; 56% reduction CUALs in the brain; reduction in fatigue symptoms; safety profile is consistent with the previous studies
  • Ponesimod is an investigational S1P1 modulator, act by inhibiting S1P activity leading to a reduction in the number of circulating lymphocytes crossing the BBB  

Click here ­to­ read full press release/ article | Ref: J&J | Image: Janssen